P450-Based Nano-Bio-Sensors for Personalized Medicine by Baj-Rossi, Camilla et al.
21 
P450-Based Nano-Bio-Sensors 
for Personalized Medicine 
Camilla Baj-Rossi, Giovanni De Micheli and Sandro Carrara 
EPFL - École Polytechnique Fédérale de Lausanne  
Switzerland 
1. Introduction 
Cytochromes P450 (P450s or CYPs) belong to a multigene family of more than 3,000 heme 
proteins which catalyse the NADPH-dependent monooxygenation and other about 60 
distinct classes of biotransformation reactions. Cytochromes P450 are known to be involved 
in the metabolism of over 1,000,000 different xenobiotic and endobiotic lipophilic substrates 
(Shumyantseva, Bulko, Archakov, 2005).  Cytochrome P450s carry out a wide array of 
metabolic activities that are essential to homeostasis, apart from their roles in steroid 
biosynthesis and biotransformation and drug or toxin clereance. In figure 1, the 
tridimensional structure of cytochrome P450 3A4 is reported. 
 
 
Fig. 1. Structure of cytochrome P450 3A4 (obtained by PDBe Protein Databank Europe 
http://www.ebi.ac.uk/pdbe/). 
The liver is the main organ responsible for the biotransformation of drugs and chemicals, 
even if the gut metabolizes many drugs, and the CYPs and other metabolizing enzymes 
reside in the hepatocytes (Fig. 2). Basically, the primary function of CYPs and other 
biotransforming enzymes is to make very oil-soluble molecules highly water-soluble, so that 
they can be easily cleared by the kidneys into urine and they will be finally eliminated. 
When the drugs or toxins reach the hepatocytes in the liver, they basically flow inside the 
walls of the tubular structure of the smooth endoplasmic reticulum (SER), entering into the 
path of the CYP monooxygenase system. This is a highly liphophilic environment that keeps 
the liphophilic molecules away from the aqueous areas of the cell and allows the CYPs to 
metabolize them into more water-soluble agents (Coleman, 2010). 
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Fig. 2. Location in the hepatocyte of CYP enzymes and their redox partners, cytochrome b5 and 
P450 oxidoreductase (POR), (Coleman, 2010). Reprinted with permission from Coleman, 2010.  
Copyright 2010 Wiley-Blackwell (John Wiley & Sons, Ltd). 
Cytochromes P450 are enzymes involved in the metabolism of ∼75% of all drugs (Figure 
3A). Of the 57 human P450s, five are involved in ∼95% of biotransformation reactions 
(Figure 3B), and each one is specific for a certain fraction of reactions which involved 
different substrates (Guengerich, 2008). In all living things, over 7,700 individual CYPs have 
been described and identified, although only 57 have been identified in human hepatocytes; 
of these, only 15 metabolize drugs and other chemicals.  
 
 
Fig. 3. Contributions of enzymes to the metabolism of marketed drugs. (A) Fraction of 
reactions on drugs catalyzed by various human enzymes. FMO, flavin-containing 
monoxygenase; NAT, Nacetyltransferase; and MAO, monoamine oxidase. (B) Fractions of 
P450 oxidations on drugs catalyzed by individual P450 enzymes (Guengerich, 2008). 
Reprinted with permission from Guengerich, 2008.  Copyright 2008 American Chemical 
Society. 
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2. Cytochrome P450: classification and polymorphism 
Cytochromes P450 are classified according to their amino acid sequence homology, that is, if 
two CYPs have 40 per cent of the full length of their amino acid structure in common they 
are thought to belong to the same ‘family’. More than 780 CYP families have been found in 
nature in total, but only 18 have been identified in humans. Subfamilies are identified as 
having 55 per cent sequence homology and there are often several subfamilies in each 
family (Coleman, 2010). The nomenclature for P450s is based on naming cytochromes P450 
with CYP followed by a number indicating the gene family (such as CYP1, CYP2, CYP3, 
etc.), a letter indicating the subfamily (i.e. CYP1A, CYP2A, CYP2B, CYP2C, etc.) and a 
number for the gene that identify the so named ‘isoform’. In order to have the same gene 
number the genes must have the same function and exhibit high conservation (Ingelman-
Sundberg, 2004). That is, two isoforms (e.g. CYP1A1 and CYP1A2) have 97 per cent of their 
general sequence in common. The completion of the sequence of the human genome 
revealed the presence of about 107 human P450 genes: 59 active and about 48 pseudogenes 
(Ingelman-Sundberg, 2004). The majority of genes exhibit a certain polymorphism (which is 
generally defined as 1% frequency of an allelic variant in a population) which leads to 
classify the CYPs even according to these allelic differences. A polymorphic form of a CYP is 
usually written with a * and a number for each allelic variant, or translated version of the 
gene. Regarding the polymorphic forms, they might contain one or more single nucleotide 
polymorphism (SNP, i.e. a change in one nucleotide of the genetic code) in the same allele 
(Coleman, 2010). For example, CYP2B6 has eight other significant allelic variants besides its 
major form, and among this variants, CYP2B6*4 has just one SNP, whilst CYP2B6*6 
possesses two SNPs. The clinically most important polymorphism is seen with CYP2C9, 
CYP2C19 and CYP2D6. The functional importance of the polymorphisms of the xenobiotics 
metabolizing CYPs is summarized in Table 1. 
The mutations in the CYP genes can cause the enzyme activity to be abolished, reduced, 
altered or increased, with substantial consequences in drug metabolism (Ingelman-
Sundberg, 2004). Based on the composition of the alleles, the affected individuals might be 
divided into four major phenotypes: poor metabolizers (PMs), having two nonfunctional 
genes, intermediate metabolizers (IMs) being deficient on one allele, extensive metabolizers 
(EMs) having two copies of normal genes and ultrarapid metabolizers (UMs) having three 
or more functional active gene copies (Ingelman-Sundberg, 2004; Rodriguez-Antona, 2006). 
Phenotyping usually involves administering a single probe drug for a particular enzyme 
and measuring clearance and comparing it with data from other patients. The clinical 
influence of differences in CYP activity can be schematized as reported in figure 4. In this 
model example, only EMs and PMs are reported as the general population of interest. 
Referring to the EMs metabolizers (upper panel in figure 4), it is visible that after drug 
administration the plasma concentration rises to a peak (Cp,max) following the first dose and 
then decrease to a lower level prior to the next dose. With subsequent doses, the plasma 
concentration remains within this region and yields the desired pharmacological effect. 
Without prior knowledge about a problem with this drug, the PM (lower panel of Figure 4) 
and EM would be administrated the same dose. For PMs, a limited metabolism would occur 
between doses, and the plasma concentration of the drug will rise to an unexpectedly high 
level. The simplest effect would be an exaggerated and undesirable pharmacological 
response (Ortiz de Montellano, 2005).  
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CYP enzyme Substrates 
Polymorfism 
Frequency Functional effects Most important 
polymorphic variants 
CYP1A1 Carcinogens Relatively high - - 
CYP1A2 Drugs, carcinogens High Some CYP1A2*1F, 
CYP1A2*1K 
CYP2A6 Nicotine, drugs, 
carcinogens 
High in orientals, 
less frequent in 
Caucasians 
Important for nicotine 
metabolism 
CYP2A6*1B, 
CYP2A6*4, CYP2A6*9, 
CYP2A6*12 
CYP2B6 Drugs High Reduced drug 
metabolism 
CYP2B6*5, CYP2B6*6, 
CYP2B6*16 
CYP2C8 Some drugs High Reduced drug 
metabolism 
CYP2C8*3 
CYP2C9 Drugs Relatively low Very significant CYP2C9*2, CYP2C9*3 
CYP2C19 Drugs High Very significant CYP2C19*2, 
CYP2C19*3, 
CYP2C19*17 
CYP2D6 Drugs High Very significant CYP2D6*2, CYP2D6*4, 
CYP2D6*5, 
CYP2D6*10, 
CYP2D6*17 
CYP2E1 Carcinogens, 
solvents, few 
drugs 
Low No - 
CYP3A4 Drugs, carcinogens Low No or small CYP3A4*1B 
Table 1. Polymorphic cytochromes P450 of importance for drugs and carcinogens 
metabolism (Guengerich, 2001; Ortiz de Montellano, 2005). 
At present state-of-the-art the only available monitoring system for personalized therapy is 
a check of the genetic predisposition of patients. In order to know which patient is at risk of 
having sub-therapeutic or toxic drug concentrations, a genetic test is done on alleles, which 
correspond to patient genetic predisposition for expressing the CYP proteins (Kirchheiner & 
Seeringer, 2007). A genetic test based on microarray has been introduced into the market by 
Roche: the Amplichip CYP450 (Amplichip, Figure 5).  
It is the first FDA-cleared test for analysis of CYP2D6 and CYP2C19, two genes in the 
cytochrome P450 system that can greatly influence drugs metabolism. This test identifies the 
patient's genotype group and predicts his phenotype in order to classify patients as an either 
poor, intermediate, extensive, or ultra-rapid metabolizer. It was proven that this classification 
affects the actual amount of mean plasma concentration after a single drug dose (Lin, 2007).  
However, the Amplichip can only “predict” the patient’s phenotype and can only allow the 
adjustment of drug dose according to patient’s genotype (as schematized in Figure 6). In Fig. 
6, the theoretical dosages for different genotypes including ultrarapid, extensive, 
intermediate or slow metabolic activity are reported. They have been calculated from the 
differences in pharmacokinetic parameters and are depicted as schematic genotype-specific 
dosages, in order to have the same plasma-concentration course for all genetic group 
(Kirchheiner & Seeringer, 2007). Thus, in order to individually optimize an ongoing drug 
therapy, it is required to know how the patient metabolize drugs at the moment of the 
pharmacological cure, i.e. it is necessary to measure the plasma concentrations of drugs or 
their metabolites after the administration. This is a strong need since still most effective drug 
therapies for major diseases provide benefit only to a fraction of patients, typically in the 20 
to 50% range (Lazarou et al., 1998). 
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Fig. 4. Examples of unexpectedly low metabolism of a drug by P450s. The typical pattern 
seen with the majority of the population (extensive metabolizers) is shown in the upper 
panel, where the plasma level of the drug is maintained in a certain range after the 
administration of several consecutive doses (arrows indicate multiple doses). Unusually 
slow metabolism (lower panel) occurs when a poor metabolizer receives the same dose, 
resulting in unexpectedly high plasma level of the drug (Guengerich, 2003). Reprinted with 
permission from Guengerich, 2003. Copyright 2003 Molecular Interventions Online by the 
American Society for Pharmacology and Experimental Therapeutics. 
 
 
Fig. 5. Amplichip CYP450 (Roche). ROCHE and AMPLICHIP are trademarks of Roche. 
AFFYMETRIX  and POWERED BY AFFYMETRIX are trademarks of Affymetrix, Inc. 
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Fig. 6. Principle of calculation of genotype based dose adjustments based upon differences 
in pharmacokinetic parameters such as clearance and AUC. (Kirchheiner & Seeringer, 2007). 
Reprinted from Biochimica et Biophysica Acta, Vol. 1770, Julia Kirchheiner, Angela 
Seeringer , “Clinical implications of pharmacogenetics of cytochrome P450 drug 
metabolizing enzymes”, Pages No. 489–494, Copyright (2007), with permission from 
Elsevier. 
In general, there are only three CYP families which are mainly involved in drug and toxin 
biotransformation for humans, including: 
 CYP1 family (CYP1A1, CYP1A2 and CYP1B1); 
 CYP2 family (CYP2A6, CYP2A13, CYP2B6, CYP2C8, CYP2C9, CYP218, CYP219, CYP2D6, 
CYP2E1); 
 CYP3 family (CYP3A4, CYP3A5, CYP3A7). 
It is known that the 90% of marketed drugs are metabolized by only five of these isoforms 
(CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4/5), (Ingelman-Sundberg, 2004). 
3. Active-site structure of P450 enzymes 
Although CYPs in general are capable of metabolizing almost any chemical structure and 
catalyse around 60 different classes of biotransforming reactions, they have a number of 
features in common, including (Coleman, 2010): 
a. Most mammalian CYPs exist in the lipid smooth endoplasmic reticulum (SER) 
microenvironment, being partially embedded in the liphophilic membrane of the SER 
and their access channels are actually positioned inside the membrane ready to receive 
substrates, which are normally liphophilic (see Figure 2). 
b. CYPs possess in their inner structure a heme group in their active site containing iron, 
which is a highly conserved part of their structures, and it is crucial for their catalytic 
activity. This active-site area is quite rigid, but it is surrounded by much more flexible 
complex binding areas, which can be regulated with different conformational changes 
in order to allow the entrance of different-size molecules. 
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c. CYPs have one or more binding area inside their active site, which determine for most 
part their variations and their ability to metabolize specific groups of chemicals. 
d. Thanks to the heme group, CYPs exploit the ability of a metal to gain or lose electrons, 
thus catalyzing substrate oxidations and reductions, according to the NADPH-
monooxygenation pathway. 
e. All CYPs have closely associated redox partners, the cytochrome b5 and P450 
oxidoreductase (POR), able to supply them with electrons for their catalytic activities 
(Figure 2). 
f. All CYPs bind and activate oxygen in their catalytic cycle as part of the metabolism 
process, but they are also able to carry out reduction reactions that do not require the 
presence of oxygen. 
CYP enzymes share a common overall fold and topology (Figure 7) despite the differences 
in the genetic sequences and the genetic polymorphism. The conserved CYP structural core 
is formed by a four-α helix bundle composed of three parallel helices labelled D, L, and I 
and one antiparallel helix E (Denisov et al., 2005). The whole enzyme structure is usually 
anchored in the membrane of the smooth endoplasmic reticulum by an N-terminal α helix. 
The α helices hold in place the active site of the enzyme, the heme-iron group. In most CYPs 
the heme group is a relative rigid part of the protein’s structure. The heme moiety (Figure 8), 
also known as ferriprotoporphyrin-9, has a highly specialized lattice structure that supports 
a iron molecule, which is the core of the enzyme and is the responsible of the substrate 
oxidation  (Coleman, 2010). 
 
 
Fig. 7. Ribbon representation (distal face) of cytochrome P450s fold. Substrate recognition 
sites (SRS) are shown in black and labelled. α-Helixes are labelled with capital letters 
(Denisov et al., 2005). Reprinted with permission from Denisov et al., 2005. Copyright 2005 
American Chemical Society. 
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The iron atom is normally bound to five other molecules which keep it secured; four of them 
are pyrrole nitrogens and hold it in the horizontal plane while the fifth group, a sulphur 
atom from a cysteine amino acid residue links the iron in a vertical plane. This structure, 
known as the pentacoordinate state, represent the resting state, whilst the hexacoordinate 
state occurs when the iron binds another ligand. In this latter configuration, the iron atom 
appears to move ‘upwards’ and draws level with the nitrogens to bind a water molecule 
which is hydrogen bonded to an amino acid residue and is involved in the movement of 
protons during the catalytic activity. The ferriprotoporphyrin-9 is held in place by hydrogen 
bonding and a number of amino acid residues. The iron is crucial to the catalytic function of 
CYP enzymes. 
 
 
Fig. 8. Heme group chemical structure (Sono et al., 1996). Reprinted with permission from 
Sono et al., 1996. Copyright 1996 American Chemical Society. 
The other helices that cover the active site are the flexible regions of the structure. They are 
normally partially clenched, but can open out to accommodate large substrates. The 
liphophilic substrate molecules diffuse through the membrane and enter the isoform 
through a sort of access path, which is defined as the widest, shortest and usually the most 
liphophilic pathway to reach the heme iron active site. The active site is supplied with 
electrons by the dual redox partners, the cytochrome b5 and P450 oxidoreductase (POR), 
trough another access channel from the other side of the CYP (see Figure 9). These redox 
partners are also embedded in the smooth endoplasmic reticulum membrane right next to 
the CYP (see Figure 2). After the catalytic reaction, the transformed products naturally exit 
the isoform trough another channel (Coleman, 2010). Figure 9 shows the structure of 
cytochrome P450 14α-sterol demethylases (CYP51) with the open substrate access channel 
between the β-sheet and helical domains (channel 2) oriented approximately 90° relative to 
CYP51 channel 1. Those channels, delimited by the F, G, and H helices and loops in 
between, are known to undergo synchronized motions in CYPs when substrate binds. This 
synchronization allows the channel 1 to open, whereas channel 2 remains closed, thus 
providing a means for substrate to enter one channel and product to depart from the other 
(Podust et al., 2001).  
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Fig. 9. Ribbon representation of the CYP51 structures with the azole inhibitors bound 
(Podust et al., 2001), which shows the two access channels (channel 1 and 2). Reprinted with 
permission from Podust et al., 2001. Copyright (2001) National Academy of Sciences, U.S.A. 
3.1 Substrate binding in CYPs  
The active site of an enzyme usually refers to a binding area which holds the substrate in a 
proper orientation capable to present the molecule to the structure of the enzyme that catalyze 
the reactions. In many enzymes, the dimensions and properties of the active and binding sites 
are quite well defined and mapped in detail, but crystallographic studies (Coleman, 2010), 
have shown that in the case of CYPs is difficult to define what constitutes the active binding 
site and to correctly identify their structure. As an example, it is known that CYP3A4, CYP2C8 
and CYPC29 have very large active sites, whilst that of CYP2A6 is quite small. Cytochrome 
P450 undergo big changes in movement and binding area to accommodate substrates of 
differing sizes, thanks to the small-intermediate hydrophobic pockets placed into the CYP 
active site, with the capability as the α-helices to extend its area to bind larger substrates. The 
hydrophobic pocket (Figure 10) includes many amino acid residues that can bind a molecule 
with hydrogen bonding, weak van der Waals forces, or other interactions between electron 
orbitals of phenyl groups, such as π-π bond stacking. It is known that the isoform CYP3A4 can 
increase its active site area by 80 per cent to accommodate erythromycin (Coleman, 2010).  
The presence of several amino acid residues allows the active site to provide a grip on the 
substrate in a number of places in the molecule preventing excessive movements while, 
when not binding substrates, CYP active site area is full of water molecules displaced upon 
the binding site. Moreover the substrate binding may occur in the interior and exterior 
structure of the isoform, and also the binding may involve internal rearrangement of the 
isoform or involve simultaneous binding of other substrates. At the simplest structural level 
it is possible to identify six different active sites or “substrate recognition sites” (SRS, see 
Figure 7), which predetermine CYP substrate specificity (Denisov et al., 2005). It has been 
reported that several CYP isoforms, including 3A4, 1A2, 2E1, 2D6, and 2C9, exhibit 
allotropic kinetics in vitro (Atkins, 2005). This atypical kinetic behaviour is typical of the 
enzymes that shows multiple substrate recognition sites in their active site, as CYPs, and is 
basically due to the conformational or chemical changes that occur in the active site of the 
enzyme after binding a first substrate (the effector). These changes in the conformation of 
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enzyme tertiary and quaternary structure result in the enzyme catalytic activity alteration 
which can affect the metabolism of a second substrate (Houston & Galetin, 2005). 
 
 
Fig. 10. The substrate binding cavity (meshed surface) of human cytochrome P450 3A4 
(obtained by PDBe Protein Databank Europe, http://www.ebi.ac.uk/pdbe/). Molecular 
oxygen is reduced by the heme prosthetic group (the cyan stick figure) to form a reactive 
intermediate that oxygenates the substrate.  
3.2 Redox partners and electron transport system 
In catalyzing monooxygenation reactions of a substrate RH, CYP is able to utilize either 
NADH or NADPH (nicotinamide adenine dinucleotide and nicotinamide adenine 
dinucleotide phosphate respectively) as the electron donor (equation 1).  
 RH + O2 + NAD(P)H + H+ → ROH + H2O + NAD(P)+ (1) 
However, the two electrons derived from NAD(P)H must be transferred to CYP via electron 
transport proteins called  redox partners. The main CYP redox partners are the P450 
oxidoreductase and the cytochrome b5 (Sevrioukova et al., 1999): 
a. P450 oxidoreductase (POR) is a flavoprotein complex, that consists of a large butterfly-
shaped protein which locates and binds two flavins that work as electron carriers, FAD 
(flavin adenine dinucleotide) and FMN (flavin mononucleotide) in two separate lobes 
of the P450 oxidoreductase structure. The oxidative system, which consumes the 
glucose in the liver by the pentose phosphate pathway, produces NADPH to power all 
reductive reactions related to CYPs, and other reactions. P450 oxidoreductase complex 
operates as follows (Figure 11): electrons from reduced NADPH (released as NADP+), 
are taken up by the FAD moiety, which is reduced to FADH2. Then FADH2 reduces 
FMN to FMNH2, which in turn passes its two electrons to the CYP heme group, which 
is associated with the P450 oxidoreductase by electrostatic interactions (Huang et al., 
2008). This electron transfer becomes a current of electron that P450 oxidoreductase 
must supply in the presence of high substrate concentrations. 
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Fig. 11. Relationship of P450 oxidoreductase to a microsomal cytochrome P450 enzyme 
(Huang et al., 2008). ER is the endoplasmic reticulum and CYTO is the cytoplasm. Adapted 
from (Miller, W.L., 2005). Reprinted with permission from Huang et al., 2008. Copyright 
(2008) National Academy of Sciences, U.S.A. 
b. Cytochromes b5 (Figure 12) are electron transport hemeproteins which, similarly to 
cytochrome P450, are built around a central heme group. In nature these proteins 
convert in the cells NADH to NAD+, building up proton gradients which stimulate the 
flow of electrons. There are numerous forms and structures of cytochrome b5, but the 
microsomal cytochrome b5 is of greatest interest in drug metabolism. Microsomal 
cytochrome b5 is anchored by a helix into the smooth endoplasmic reticulum membrane 
(see Figure 2), but its heme structure, which is not-covalently linked with its CYP 
isoform, is closely associated with P450 oxidoreductase. Cytochrome b5 has a complex 
but also essential role in CYP function. The standard CYP catalytic cycle (see paragraph 
4) requires two electrons to reach a complete turn. The second electron is the rate 
limiting step in the enzymatic catalytic activity, and the cytochrome b5 can supply this 
electron with high speed, even quicker than the system composed by P450 
oxidoreductase and NADPH (Coleman, 2010). 
 
 
Fig. 12. Cytochrome b5 structure (obtained by PDBe Protein Data Bank Europe, 
http://www.ebi.ac.uk/pdbe/). 
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4. Cytochrome P450 catalytic cycle 
After having understand the complex structure of these enzymes, it is necessary to know 
that all of them essentially function in the same way, despite the genetic differences. CYPs 
can carry out substrate (RH) reductions through a catalytic cycle after substrate and oxygen 
binding. However, their main function is to insert an oxygen molecule into a usually stable 
and hydrophobic compound, and the global reaction can be schematized with the following 
equation (Coleman, 2010): 
 Hydrocarbon (-RH) + O2 + 2 electrons + 2H+ → alcohol (-ROH) + H2O (2) 
The CYP reduction activity is carried out through the so-called catalytic cycle (figure 13), 
which will be briefly reported in a simple way, considering the many details involved in this 
complex process (Sligar, 1976). 
 
 
Fig. 13. CYP catalytic cycle (Denisov et al., 2005). Reprinted with permission from Denisov 
et al., 2005.  Copyright 2005 American Chemical Society. 
a. Substrate binding (1-3). The first step is the binding and orientation of the substrate 
molecules. The iron is usually in the ferric form when the substrate is bond: 
Fe3+ - RH 
The substrate binds to the active site of the enzyme, in close proximity to the heme 
group. The bound substrate induces a change in the conformation of the active site, 
displacing a water molecule from the distal axial coordination position of the heme 
iron, and changing the state of the heme iron from a low-spin (LS) to an high-spin (HS) 
substrate-bound complex (2). The HS ferric enzyme (Fe3+) has a more positive reduction 
potential and thus in CYP is much easier reduced. Once the substrate has been bound, 
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the next stage is to receive the first of two electrons from the redox partners, so 
reducing the iron to its ferrous state Fe2+ (3): 
Fe2+ - RH 
b. Oxygen binding (3-4). The next stage involves the binding between ferrous substrate-
bound complex and molecular oxygen. This process is usually faster than the previous 
one, since in the cell there is much more oxygen than substrate: 
O2 - Fe2+ - RH 
Oxygen binding leads to a slow rearrangement of the Fe2+O2 complex to form an oxy-
P450 complex (4), which is the last relatively stable intermediate in this cycle: 
O- - O – Fe3+ - RH 
However, this sometimes allows the bond to dissociate, trough the so-called 
"autoxidation shunt", releasing a reactive superoxide radical, with the return of the 
enzyme to its resting state, thus interrupting the catalytic cycle (Denisov et al., 2005). 
c. Oxygen scission (splitting), (4-5a). This is the crucial stage that decides if the substrate will 
be oxidized or not and it is the rate-limiting step of the cycle. A second electron 
supplied by the redox partners feeds into the complex and forms a peroxo-ferric 
intermediate (5a): 
O2- - O – Fe3+ - RH 
As explained earlier, cytochrome b5 may supply this second electron faster than 
NADPH reductase.  
d. Protonation of peroxo-ferric intermediate (5a-6). The peroxo group formed in the previous 
step is rapidly protonated by surrounding amino-acid side chains forming an 
hydroperoxo-ferric intermediate (5b) and then is secondly protonated at the distal 
oxygen atom. Then, a subsequent heterolysis of O-O bond occurs with the release of a 
mole of water and the formation of a highly reactive iron (IV)-oxo species (6). 
e. Insertion of the oxygen into substrate (6-7). Depending on the substrate and enzyme 
involved, P450 enzymes can catalyse a wide variety of reactions (a complete list is 
reported in Figure 14). A hypothetical hydroxylation is shown in the illustration (Sono 
et al., 1996). The substrate can be activated by either removing hydrogen (hydrogen 
abstraction) or an electron (e.g. from nitrogen atoms), from the substrate molecule. The 
hydrogen abstraction leaves the carbon with a spare electron making it a reactive 
radical (6) and then much more likely to react with the hydroxyl group. The final stage 
is the reaction between the newly created hydroxyl group and the carbon radical, 
leading the alcohol formation (7). 
f. Release of product (7-new cycle). Now the substrate, converted to a metabolite, has 
changed both structurally and chemically and cannot be longer bound to the active site 
of the CYP. The product is thus released and the CYP isoform returns to its original 
resting state (1), with a water molecule returning to occupy the distal coordination 
position of the iron nucleus, now ready for binding another substrate molecule.  
In addition the P450 reaction cycle contains at least three branch points, where multiple side 
reactions are possible and often occur under physiological conditions.  The three major 
abortive reactions are (i) autoxidation (autoxidation shunt) of the oxy-ferrous enzyme (4) with 
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Fig. 14. Schematic summary of the diverse P450-catalyzed reactions (Sono et al., 1996). 
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the production of a superoxide anion and return of the enzyme to its resting state (2), (ii) a 
peroxide shunt, where the hydroperoxide anion (5b) dissociates from the iron forming 
hydrogen peroxide, thus completing the unproductive  reduction of oxygen, without 
substrate turnover, and (iii) an oxidase uncoupling wherein the ferryl-oxo intermediate (6) is 
oxidized to water, which results effectively in the reduction of dioxygen molecule with the 
formation of two molecules of water. These processes are often categorized together and 
referred to as uncoupling reactions (Denisov et al., 2005). Cytochrome P450 catalyzes 
different types of reactions, illustrated in the Figure 14, which are all based on the same 
catalytic cycle.  
5. Cytochrome P450 for drug-biosensor 
Electrochemical investigations are usually performed on enzymes to determine fundamental 
parameters, such as the redox potential, and the electron transfer between the enzymes and 
the electrodes (Armstrong & Wilson, 2000). Electrochemical studies of cytochromes P450 are 
of great interest due to the possibility of developing applications such as biosensors for 
analyte detection and electrochemical catalysis for product synthesis (Honeychurch, 2006). 
CYPs ability to metabolize a broad spectrum of endogenous substances, e.g., fatty acids, 
steroid hormones, prostaglandins and foreign compounds (e.g. drugs and environmental 
toxins), has made this enzyme family interesting as recognition element for biosensing 
(Bistolas et al., 2005). At the present state-of-the-art, methods such as gas chromatography-
mass spectrometry and high-performance liquid chromatography are used for in vitro 
quantifying the levels of drugs and their metabolites in blood and plasma. These 
commercially-available methods are time-consuming and expensive. Although with these 
methods is possible to obtain rapid quantitative in vitro diagnosis with high accuracy, they 
require time-consuming sample preparation. Thus, these techniques are not so widely 
spread for practical industrial and medical applications (Iwuoha et al., 2007; Shumyantseva 
et al., 2004). A cytochrome P450 biosensor may be a promising alternative that would 
provide quick measurements for drugs and metabolites with a cheap, simple to use, rapid 
and in some instances disposable equipment, which also supply good selectivity, accuracy 
and sensitivity.  
After the first studies in the 1970s (Bistolas et al., 2005), when CYPs contained in intact 
hepatocytes and microsomes were used in extracorporal detoxification reactions, choosing 
as target a wide range of substrates which are subjected to hydroxylation by CYPs, many 
attempts were carried out in order to built up a CYP-based biosensor for the detections of 
molecules of interest and drugs. In order to provide stability to the enzyme-system and in 
order to avoid the need of the regeneration of cofactor NADH and NADPH, which naturally 
provide electrons to the cytochrome active site, amperometric biosensors of second and 
third generations (Figure 15) were thought to be the most suitable for such applications and 
were designed. Some attempts have been recently made to improve the electron transfer 
between the CYP-enzymes and the electrodes, through the employment of en 
electrochemically active mediator and using cathodic current for the substrate reduction, 
thus obtaining highly efficient electrochemical second-generation biosensor (Shumyantseva 
et al., 2000). As found in literature, cobalt(III) sepulchrate trichloride was used as mediator 
for the electrocatalytical reduction of proteins containing different cytochrome P450s and 
NADPH-P450 reductase for catalyze the hydroxylation of steroids and the N-demethylation 
of drugs (Estabrook et al., 1996). Otherwise mediators such as FMN, FAD or riblofavins 
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(Shumyantseva et al., 2000, 2001) were covalently bound to cytochrome P450 2B4 and 1A2 
cross-linked onto a screen-printed rhodium graphite electrode for direct amperometric 
measurement of cholesterol or aminopyrine. Unfortunately, this kind of redox mediators 
used in conjunction with redox enzymes facilitates not only the electron transfer between 
electrode and enzyme but also other various interfering reactions, resulting in a low-
specificity detection.  
 
 
Fig. 15. Representation of three different amperometric biosensors generations (Freire et al., 
2003). The first-generation biosensors (Fig. 15 A) are based on direct electrochemical 
detection of substrate or product of the enzyme reaction, while in the second and third-
generation biosensor the detection is based on the quantification of the electron transfer. In 
the second-generation biosensors (Fig. 15 B), molecular oxygen is replaced with other 
reversible oxidizing agents, called mediators Mox, which, are small redox active molecules 
(e.g., ferrocene derivates, ferricyanide, conducting organic salts and quinones) that could 
react both with the active site of the enzyme and with the electrode surface, realizing the 
electron transfer between the enzyme and the electrode. In the third generation-biosensors 
(Fig. 15 C) a direct electron transfer occurs, without using any kind of mediators. In third 
generation-biosensors several enzymes able to catalyse direct (mediatorless) electron 
transfer are used. Reprinted with permission from Freire et al., 2003. Copyright 2003 
Sociedade Brasileira de Química. 
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The most suitable approach for the design of a CYP-based biosensor is the direct 
mediatorless electron supply from an electrode to the redox active group of the CYP, thus 
leading a direct flow of electrons between the enzyme and the electrode. This kind of 
biosensor (third-generation biosensors) usually offers better selectivity, because they are 
able to operate in a potential range closer to the redox potential of the enzyme itself, 
becoming less exposed to reactions with interferents. The electrode is used as electron 
source for the CYP cathodic reduction which is coupled with the substrate transformation. 
The generation and the measurement of a catalytic current is the direct indicator of CYP-
dependent electrocatalysis. In the figure 16 is reported a scheme for the electrocatalytic 
oxygenation reaction of a substrate (RH) bound to CYP immobilized onto the electrode 
surface. In this scheme is possible to observe the active role of electrode as electron source in 
the P450 catalytic cycle.  
 
 
Fig. 16. Suggested scheme for the electrocatalytic oxygenation reaction of substrate-bound 
cytochrome P450 (Iwuoha et al., 1998). Reprinted from Journal of Pharmaceutical and 
Biomedical Analysis, Vol. 17, Emmanuel I. Iwuoha, Shiba Joseph, Z. Zhang, Malcolm R. 
Smyth, Uwe Fuhr, Paul R. Ortiz de Montellano, “Drug metabolism biosensors: 
electrochemical reactivities of cytochrome P450cam immobilised in synthetic vesicular 
systems”, Pages No. 1101–1110, Copyright (1998), with permission from Elsevier.  
In the development of this mediator-less approach, the immobilization of CYP onto the 
electrode surface has to be deeply controlled in order to obtain a high probability for the 
protein to be attached to the electrode in a proper orientation that could optimize the 
electron transfer to the heme group since it is deeply immerged in the cytochrome structure. 
In addition, the immobilization techniques of CYPs onto the electrode should avoid the 
formation of an insulating protein layer which prevents electron transfer, due to the 
adsorptive denaturation of proteins onto metal electrodes (Eggins, 2003). 
5.1 CYPs immobilization techniques 
The electron transfer between the enzyme and the electrode depends mostly on the 
technique used for the protein immobilization, on the electrode material or on the method 
used for modify the electrode surface, because all these factors change the orientation and 
the distance of the protein from the electrode. A variety of metal electrodes such as Au, Pt, 
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Tin oxide, oxide electrodes (such as In2O3), as well as non-metal electrodes such as glassy 
carbon, graphite (pyrolytic graphite and edge-plane graphite), and carbon cloth has been 
used for the fabrication of CYP-based amperometric biosensors (Bistolas et al., 2005; 
Eggins, 2003). Electrodes fabricated by screen-printed technology have been widely used 
for the design of amperometric-enzyme biosensors, thanks to their high selectivity and 
sensitivity, low cost, portable field–based size and their great versatility in the wide range 
of ways in which the electrodes can be modified (Renedo et al., 2007). Enzymes tend to 
denature and to passivate the electrode on not-modified metal electrodes, forming an 
insulating protein layer which prevents electron transfer. Electrochemical measurements 
has been carried out with CYPs immobilized onto bare electrode (Bistolas et al., 2005), 
showing that CYPs were absorbed onto the electrode surfaces but the electron transfer 
estimated with these systems was low and poorly efficient (Fantuzzi et al., 2004). It is 
necessary to keep under control both the concentration at the electrode surface and the 
orientation of the enzyme, in order to improve the sensor sensitivity. The inclusion of 
CYPs in an appropriate medium like a conductive polymer or the non-specific absorption 
of CYPs onto metal electrode modified with nanomaterials, can lead to the formation of a 
non-controllable and randomly orientated layer of enzymes. On the other hand, an 
orientated packed enzyme-monolayer covalently bonded to the electrode surface could be 
realized through the specific functionalization of both the CYPs ends and the metal 
surface. More in general, there are different techniques for the CYPs immobilization and 
the electrode surface modification which depend on the applications, but all of them 
avoid protein denaturation and preserve an appropriate orientation thus increasing 
electron transfer. Here, the main techniques used for modify the electrode surfaces are 
reported: 
a. Clay nanoparticles-modified electrodes. Clay minerals are usually ion-exchangeable 
aluminosilicates, very widespread in geologic deposits. The mineral group of clays 
includes sodium montmorillonite, smectite, laponite, kaolinite, talc, goethite and orche. 
Clay particles are very small and their size is comparable with protein sizes so that they 
are really effective for mediate the electron transfer between electrode and 
biocomponent. In aqueous solutions clay produces colloid solutions with 1-100 nm size. 
Thus, clay materials can form films by dropping, casting and drying of a colloidal clay 
suspension, while with ionic surfactants they can generate biomembrane-like structures 
(Eggins, 2003; Shumyantseva et al., 2004) or can create protein-films by layer-by-layer 
technique. For instance, direct electrochemistry of cytochrome P450 at layer-by-layer 
clay modified carbon electrode was achieved (Lei et al., 2000). Sodium montmorillonite, 
kaolinite, talc, goethite and orche have been used to modify electrodes and investigate 
the electrochemistry of heme proteins (Bistolas et al., 2005). 
b. Phospholipid and vesicle-systems modified electrodes. In order to mimic the physiological 
environment of CYP enzymes, i.e. the hydrophobic environment in the endoplasmic 
reticulum of cell, synthetic phospholipids has been used for the construction of 
biosensors. These films which mimic the cellular membrane structure are surfactant 
or bilayer lipid films made by didodecyldimethylammonium bromide (DDAB), 
dimeristoyl-l-phosphatidylcholine (DMPC), dilauroylphosphatidylethanolamine 
(DLPE) and distearoyl-phosphatidyl-ethanolamine (DSPE). The phospholipid layer-
structure may facilitates electron transfer between the enzymes redox centre and the 
electrode. Stable films can be cast onto surfaces from solution of surfactants in 
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organic solvents or from aqueous vesicle dispersion, since the surfactants are 
insoluble in water. Then evaporation of solvent leads the surfactant to auto-assembly 
into phospholipid biomembrane-like films (Wu & Hu, 2007). In some studies (Iwuoha 
et al., 1998), CYPs were incorporated in vesicle dispersion of the synthetic material 
DDAB and then immobilized by cross-link onto glassy carbon electrode. Other 
applications involving CYPs for biosensor production used glutaraldehyde and 
synthetic phospholipids for the immobilization of semisynthetic flavocytochromes 
based on CYP2B4, CYP1A2 and mitochondrial P450scc onto rhodium-graphite 
electrodes (Shumyantseva et al., 2001), or films of surfactants with CYP176A (Aguey-
Zinsou et al., 2003). 
c. Electrodes modified with multilayer films. In order to improve the direct electron transfer 
between electrodes and heme proteins like CYP, multilayer-deposition techniques, such 
as layer-by-layer (LBL) polyionic films of CYPs, have been studied (Bistolas et al., 2005). 
The repetition of cycles of enzyme and polyion adsorption alternately with intermediate 
washing provides multilayer stable films with reproducible amounts of enzyme in each 
layer and namometer-scale control of thickness. More than 20 enzymes and proteins 
have been incorporated into films by this electrostatic layer-by-layer self-assembly 
technique. Synthetic polyions, metal oxide nanoparticles, and biological polyions such 
as DNA have been used to alternate with the enzyme layers. Some examples are (i) Au 
and pyrolytic graphite electrodes modified by LBL film of poly-(styrenesulfonate) (PSS) 
and/or branched poly(ethyleneimine) (PEI) and CYP101 thus creating CYP101-
multilayer films (Munge et al., 2003), (ii) PSS-CYP1A2 multilayers grown on carbon 
cloth electrodes (Estavillo et al., 2003), (iii) LBL enzyme films on Au electrodes by 
alternate adsorption of a layer of CYP3A4 on top of a layer of PDDA (poly(dimethyl 
diallyl) ammonium chloride), (Joseph et al., 2003), and (iv) Polyaniline (Pan)-doped 
glassy carbon electrode (GCE) and CYP2D6 (Iwuoha, Wilson, Howel, Mathebe, 
Montane-Jaime, Narinesingh, Guiseppi-Elie, 2000).  
d. Nanomaterials. Materials in the nanometric size regime display size-dependent optical, 
electronic, and chemical properties. Nanoparticles have several advantages, such as 
large surface area, high-powered catalysis, excellent affinity, and also their nanometric-
size, since is comparable with protein size, influence the rate of electron transfer thus 
enhancing the electrochemical catalytic activity of enzymes. Several material 
nanoparticles have been used to immobilize proteins, including gold, colloidal gold 
(Wu & Hu, 2007), SiO2 (He et al., 2004; Liu et al., 2004), MnO2, ZrO2 (Liu et al., 2008; 
Peng et al., 2008) and TiO2 nanoparticles and carbon nanotubes (see paragraph 5.2.1). 
The immobilization of protein on gold nanoparticles can help the protein to keep a 
favoured orientation or to create conducting channels between the prosthetic groups 
and the electrode surface, thus reducing the effective electron transfer distance (Wu & 
Hu, 2007). It has been demonstrated (Shumyantseva, Carrara, Bavastrello, Riley, 
Bulko, Skryabin, Archakov, Nicolini, 2005) that gold nanoparticles improve the 
sensitivity of cholesterol biosensor with cytochrome P450scc. Other studies (Liu et al., 
2008; Peng et al., 2008) showed the feasibility in enhance redox current of CYP2B6 to 
be incorporated into films made by zirconium dioxide nanoparticles and platinum 
components (Peng et al., 2008) and into a chitosan modified colloidal gold 
nanoparticles (Liu et al., 2008). 
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e. Self-Assembled monolayers (Figure 17) and Langmuir-Blodgett protein films. Redox proteins 
can be adsorbed via electrostatic interaction or covalently immobilized on Self-
assembled monolayers (SAM), which can lead to a better-controlled electron transfer 
between the protein and the electrode (Yang et al., 2009). With SAMs is possible to 
regulate the distance between the heme group of CYP and the electrode surface, 
changing the chain length (the so called ‘tail’) of SAMs which allow the film to be 
tightly packed and oriented on the surface thanks to the weak interactions between the 
tails. Usually alkane-thiol or other thiol-terminated chains covalently bind the self-
assembled molecule to the metal surface of the electrode. At the other end of the chains 
a group is able to specifically interact with a group on the protein surface, thus 
adding selectivity to the modified electrode for particular proteins. Figure 17 shows 
the model of CYP2C9 bonded to the Gold-SAM electrode surface. The Langmuir-
Blodgett technique allows one to form highly ordered amphiphilic lipid monolayers 
at the air–water interface which can be used to study the interaction of proteins and 
phospholipids and to immobilize enzymes such as CYPs onto the electrode surface. 
LB monolayers offer high thermal stability thanks to the close packing of molecules 
and it has been demonstrated that its behaviour on electrodes is dependent on the 
number of monolayers (Nicolini et al., 2001). Recombinant and wild types of 
CYP11A1 (cytochrome P450scc) have been immobilized onto electrode surfaces with 
LB technique for cholesterol biosensing (Nicolini et al., 2001). Other cytochrome P450 
isoforms were immobilized by the LB technique, and used as biological recognition 
element for biosensor fabrication. The substrates chosen for the detection utilized 
were clozapine for CYP1A2, styrene for CYP2B4, and cholesterol for CYP11A1 
(Paternolli et al., 2004). 
  
 
Fig. 17. Model of CYP2C9 bonded to the Gold-SAM electrode. The gold surface/SAM to 
iron atom separation is shown (Yang et al., 2009). Reprinted with permission from Yang et 
al., 2009. Copyright 2003 Drug Metabolism and Disposition by American Society for 
Pharmacology and Experimental Therapeutics. 
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f. Sol-Gel matrix systems. This kind of bioelectrode is suitable for applications in organic 
phases. In the sol–gel immobilization onto electrode, the silicate matrix is formed 
through the acid or base hydrolysis of an alkoxide precursor, such as tetramethyl 
orthosilicate (TMOS), or more in general of the silane monomer followed by 
condensation reaction, which generate a high-density silica gel. Therefore, if a protein is 
added after the partial hydrolysis of the TMOS precursor, a porous matrix is formed 
around the protein molecule, entrapping it in an aqueous microenvironment similar to 
that of an aqueous solution of protein (Eggins, 2003). The resulting sol-gel has been 
reported to be chemically, thermally and structurally stable, with a various pore-size 
structure which is large enough to allow substrate/product diffusion into and out of the 
sol-gel network but still being small enough to prevent leaching of the enzyme. In a 
study (Iwuoha, Kane, Ania, Smyth, Ortiz de Montellano, Fuhr, 2000), a composite 
amperometric biosensor has been prepared by encapsulating a cytochrome P450cam 
/didodecyl-dimethylammonium bromide (DDAB) liquid crystal system in a 
methyltriethoxysilane (MTEOS) sol-gel.  
5.2 Electrochemical characterization of cytochrome P450 for drug sensing 
Using an amperometric biosensor, it is possible to follow the catalytic cycle of CYP by the 
quantification of the electron transfer between the electrode and the enzyme. Thus it is 
possible to indirectly measure the concentration of the drug or metabolites present in the 
sample by measuring the current in the electrochemical cell. There are several 
electroanalytical techniques for the measure of substrate concentration, such as cyclic 
voltammetry, square wave voltammetry and amperometry (Thévenot et al., 2001). Cyclic 
voltammetry (CV) is one of the mostly considered technique in electrochemistry for 
biosensing applications. Compared to other electroanalytical techniques, CV is the most 
appropriate in the case of CYP, because of the uncertainty of CYP peaks potential and 
because with CV is possible to identify more substrate molecules at a time with the same 
biological recognition element (Eggins, 2003). The biosensing is carried out by the 
measurement of the current-peaks height found in the voltammograms resulting from the 
application of a potential scan, since the height of the peaks is proportional to the 
drug/metabolite concentration, while its position in potential gives information on the 
substrate chemistry. Several attempts to measure the presence of drugs in sample have been 
carried out with cytochrome P450-based biosensors (Bistolas et al., 2005). Table 2 reports 
peaks position of different CYPs obtained trough cyclic voltammetry. It is important to 
know that the redox potential mostly depends on the method used for the CYP 
immobilization onto the electrode surface.  
Cyclic voltammograms registered with a CYP-based biosensor have different shape 
depending on some factors, such as the pH and the ionic strength of the buffer solution, the 
temperature, the immobilization technique and the scan rate, but mostly on the 
presence/absence of oxygen (O2), and obviously of the substrate (Johnson et al., 2005). 
In the absence of the CYP substrate, the mechanism of the reaction between the CYP 
immobilized onto electrode surface and O2 is outlined as follows (Guengerich, 2001):  
 P – FeIII + H+ + e-   P - FeII (3) 
 P – FeII + O2   P - FeII – O2 (4) 
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 P – FeII - O2 + e- + H+   P - FeIII + H2O2 (5) 
In the absence of oxygen in the buffer solution, one electron is first transferred from the 
electrode to the immobilized CYP (P is for the protein), leading to the reduction of the ferric 
heme iron (FeIII) to the ferrous form (FeII), according to the equation (3). This is a reversible 
electrode reaction, where one proton and the iron heme ion participate in the electron 
transfer process (Liu et al., 2008). In the presence of dissolved oxygen, the shape of the cyclic 
voltammogram visibly changed with an increase of the reduction peak current and the 
decrease of the oxidation peak current (Fig. 18). The mechanism of the reaction between the 
CYP and O2 is reported in the equations 4 and 5. Following CYP reduction, the ferrous heme 
iron of CYP (FeII) quickly binds to O2 to form the ferrous–dioxygen complex (FeII-O2, 
equation 4). This unstable highly-reactive ferrous–dioxygen complex can easily accept a 
second electron to be oxidized back to its ferric form, while the oxygen is catalytically 
reduced to H2O2 (Estavillo et al., 2003). The CYP ferric form could be reduced again, 
resulting in pronounced reduction currents observed that are typical for electrocatalytic 
oxygen reduction (Liu et al., 2008; Peng et al., 2008). In figure 18 a comparison between 
cyclic voltammograms obtained with argon-saturated buffer, air-saturated buffer and air-
saturated buffer in presence of the CYP2B6 substrate, is reported (Shumyantseva et al., 
2004). 
 
CYP species Electrode modification E° potential Reference 
CYP1A2 Multilayer with PSS-Carbon cloth 
 
PEI(/PSS/CYP) multilayer on 
pyrolytic graphite  
-310mV(vs SCE) 
 
-330mV(vs Ag/AgCl) 
(Estavillo et al., 2003) 
 
(Krishnan et al., 2009) 
CYP2B4 DDAB/Au/CYP -323mV(vsAg/AgCl) (Shumyantseva et al., 
2009) 
CYP2B6 ZrO2/Pt/PLL-film 
 
CYP/Au-chitosan/GCE 
-449mV(vsAg/AgCl) 
 
-454mV(vsAg/AgCl) 
(Peng et al., 2008) 
 
(Liu et al., 2008) 
CYP2C9 DDAB/CYP film on PGE electrode -41mV(vs NHE) (Johnson et al., 2005) 
CYP2C18 DDAB/CYP film on EPG electrode -70mV(vs NHE) (Shukla et al., 2005) 
CYP2C19 DDAB/CYP film on EPG electrode -45mV(vs NHE) (Shukla et al., 2005) 
CYP2D6 Polyaniline doped GCE -120mV(vs SCE) (Bistolas et al., 2005) 
CYP2E1 PEI(/PSS/CYP) multilayer on 
pyrolytic graphite 
-347mV(vs Ag/AgCl) (Krishnan et al., 2009) 
CYP3A4 Au-MPS-PDDA multilayers 
 
Pt-CYP-DDAB-BSA-Glu multilayers 
-470mV(vs Ag/AgCl) 
 
-689mV(vs Ag/AgCl) 
(Joseph et al., 2003) 
 
(Ignaszak et al., 2009) 
CYP11A1 Langmuir Blodgett films ITO glass 
plate 
-295 to -318mV (vs 
Ag/AgCl) 
(Bistolas et al., 2005) 
 
Table 2. List of CYP used for biosensor and their electrochemical parameters obtained with 
cyclic voltammetry technique. 
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Fig. 18. Effect of oxygen and aminopyrine on the CYP2B4 electrode with mixed film of 
CYP2B4, Tween 80, and clay (Shumyantseva et al., 2004). Reprinted with permission from 
Shumyantseva et al., 2004. Copyright 2004 American Chemical Society. 
When the drugs (substrates) are added to a buffer solution in presence of oxygen, a further 
increase of the CYP reduction current is observed (Fig. 18, spectrum of Aminopyrine), 
(Shumyantseva et al., 2004). It is known that the binding of substrates to the ferric CYP (FeIII) 
induces a change in spin state, from low spin to high spin and this change in spin state 
makes the redox potential of the enzyme shift towards more positive values, thus 
thermodynamically facilitating the transfer of the fist electron from the electrode (Liu et al., 
2008). So, the binding of the drug substrate to the enzyme promote the CYP reduction to its 
ferrous form, resulting in a faster oxygen binding and making more favorable the transfer of 
the second electron to the ferrous–dioxygen complex (Liu et al., 2008; Peng et al., 2008). 
It is possible to conclude that the coupling of the bioelectrocatalytic oxygen reduction 
current and the bioelectrocatalytic substrate conversion occurs when the substrate is added 
to a buffer solution in presence of oxygen. Indeed, this phenomenon has been verified for a 
number of different P450 enzymes in solution, including CYP101, CYP102 and CYP11A1 
(Johnson et al., 2005), and for a number of different CYPs immobilized onto electrodes, such 
as CYP2C9 (Johnson et al., 2005), CYP2B4 (Shumyantseva et al., 2004,2007), CYP3A4 (Joseph 
et al., 2003), CYP2B6 (Liu et al., 2008; Peng et al., 2008), CYP2D6 (Iwuoha et al., 2007), and 
CYP1A2 (Antonini et al., 2003; Estavillo et al., 2003). The simplified reaction scheme 
reported in figure 19, explains both the bioelectrocatalytic oxygen reduction current and the 
bioelectrocatalytic substrate conversion (Shumyantseva et al., 2004).  
The first three reactions reported in Figure 19 are respectively the substrate binding 
(reaction 1), the first electron transfer (reaction 2) and the oxygen binding (reaction 3), with 
the formation of the dioxygen-ferrous complex. The latter accepts a second electron (reaction 
4), leading to the formation of an highly reactive peroxy intermediate. The addition of 
protons H+ to this intermediate results in the insertion of an oxygen atom into the substrate 
(ROH), which is then released and the CYP is restored to its starting ferric state (reaction 5). 
The uncoupling can occur on the level of the dioxygen (reaction 6) or peroxy complex 
(reaction 7). The catalytic oxygen reduction (with the peroxide formation), regenerates the 
ferric enzyme, which may again be reduced in a further reaction cycle (reaction 2), thus 
enhancing the electrochemical reduction (Estabrook et al., 1996).  
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Fig. 19. General scheme of the electrocatalytic reaction of CYP in presence of oxygen and its 
substrate (RH), (Shumyantseva et al., 2004). Reprinted with permission from Shumyantseva 
et al., 2004.  Copyright 2004 American Chemical Society. 
Biosensors based on individual P450 proteins have already been proposed to develop novel 
tools for drug detection in human serum (Bistolas et al., 2005; Cavallini et al., 2010; 
Ghindilis, 2000). The biosensing is mainly based on the biochemical reaction schematized in 
figure 20 where a cytochrome P450 transform the redox form of a drug (the 
Cyclophosphamide in the example) in its oxidized form by using one oxygen molecules and 
two electrons.  
 
 
Fig. 20. The oxidation of a drug (Cyclophosphamide) catalyzed by the cytochrome P450. 
The two electrons (which in nature are provided by the NADPH molecules) are supplied by 
the flowing current from the electrode. As explained previously, is possible to measure this 
catalytic current and, thus, to indirectly measure the drug concentration through the  
 
 
P450-Based Nano-Bio-Sensors for Personalized Medicine 
 
471 
CYP 
species 
Drugs Description Reduction 
potential (vs 
Ag/AgCl) 
Reference 
CYP1A2 Clozapine 
 
 
Ftorafur 
Antipsychotic for 
schizophrenia 
 
Anticancer  
-265mV 
 
 
-430mV 
(Antonini et al., 
2003) 
 
* 
CYP2B4 Aminopyrine 
 
 
 
Benzphetamine 
Analgesic, anti-
inflammatory and 
antipyretic  
 
Anorectic  
-400mV 
 
 
 
-250mV 
(Shumyantseva et 
al., 2004) 
 
 
(Shumyantseva et 
al., 2007) 
CYP2B6 Bupropion 
 
Cyclophospha
mide 
 
Ifosfamide 
 
 
Lidocaine 
Antidepressant 
 
Anticancer and 
immunosuppressive  
 
Anticancer and 
immunosuppressive  
 
Anesthetic and 
antiarrhythmic 
-450mV 
 
-450mV 
 
 
-430mV 
 
 
-450mV 
(Liu et al., 2008) 
 
(Liu et al., 2008) 
 
* 
 
(Peng et al., 2008) 
CYP2C9 Diclofenac 
 
 
S-Warfarin 
 
Sulfaphenazole 
 
Tolbutamide 
 
 
Torsemide 
Analgesic and anti-
inflammatory  
 
Anticoagulant 
 
Antibacterial  
 
Stimulator for insulin 
secretion (treatment of 
type II diabetes) 
Diuretic 
-41mV 
 
 
-36mV 
 
-41mV 
 
-37mV 
 
 
-19mV 
(Johnson et al., 2005) 
 
(Johnson et al., 2005) 
 
(Johnson et al., 2005) 
 
(Johnson et al., 2005) 
 
(Johnson et al., 2005) 
CYP2D6 Fluoxetine 
 
 
 
Sertaline 
Antidepressant 
 
 
 
Antidepressant 
-327mV 
 
 
 
-275mV 
(Iwuoha, Wilson, 
Howel, Mathebe, 
Montane-Jaime, 
Narinesingh, 
Guiseppi-Elie, 2000) 
(Iwuoha et al., 2007) 
CYP2E1 P-Nitrophenol Intermediate in the 
synthesis of paracetamol 
-300mV (Fantuzzi et al., 
2004) 
CYP3A4 Cyclophospha
mide 
 
Erythromycin 
Anticancer and 
immunosuppressive  
 
Antibiotic 
-450mV 
 
 
-625mV 
* 
 
(Hendricks et al., 
2009) 
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Ifosfamide 
 
 
Indinavir 
 
Midazolam 
 
 
 
Quinidine 
 
Progesterone 
 
Verapamil 
 
Anticancer and 
immunosuppressive  
 
Anti-HIV  
 
Anxiolytic, anaesthetic, 
sedative, anticonvulsant, 
and muscle relaxant  
 
Beta blocker 
 
Steroid hormone 
 
For the treatment of 
hypertension, angina 
pectoris, cardiac 
arrhythmia 
 
-435mV 
 
 
-750mV 
 
- 
 
 
 
- 
 
- 
 
-100mV 
 
* 
 
(Ignaszak et al., 
2009) 
 
(Joseph et al., 2003) 
 
 
(Joseph et al., 2003) 
 
(Joseph et al., 2003) 
 
(Joseph et al., 2003) 
*  Measurements obtained in studies performed by the authors, immobilizing CYPs isoforms onto 
carbon nanotubes. 
Table 3. List of CYPs used for the detection of drugs for common diseases and their 
reduction potential obtained with cyclic voltammetry technique. 
analysis of reduction peaks obtained in the cyclic-voltammograms. The electron transfer can 
be enhanced by electrodes nanostructuring, as using metallic or zirconium dioxide 
nanoparticles, carbon-nanotubes (Bistolas et al., 2005; Eggins, 2003), or other techniques for 
the enzyme immobilization onto the electrode surface, which have been already explained 
in the previous pharagraph. Different studies demonstrated that carbon-nanotubes 
(schematized in figure 20) promote the electron transfer between the CYP active site and the 
electrode and enhance biosensor sensitivity (Lyons & Keeley, 2008; Wang, 2005). In table 3 a 
list of  a target drugs which have been detected with several CYP isoforms used as biological 
recognition element of biosensors is reported. 
So, the cytochromes P450 may be used to detect drug compounds commonly used in 
medical treatments by using nanoparticles or carbon nanotubes for improving the device 
sensitivity to reach the therapeutic ranges found in the patients’ serum. Since for the 
treatments some of the most common diseases, as in anti-cancer therapies, more than one drug 
are administrated contemporaneously, an array-based biosensor able to measure multiple-
drug concentrations at the same time, by using different CYP isoforms, would be very useful 
and it would find several practical applications. The development of such as biosensor has to 
overcome several difficulties, first of all the fact that each cytochrome P450 isoform detects 
many drugs and that different isoforms can detect the same drug (Carrara et al., 2009). 
5.2.1 Carbon Nanotube (CNTs) 
CNTs can be described as sp2 carbon atoms arranged in graphitic sheets wrapped into 
cylinders and can have lengths ranging from tens of nanometers to several microns 
(Lyons & Keeley, 2008). CNTs can display metallic, semiconducting and superconducting 
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electron transport, possess a hollow core suitable for storing guest molecules and have the 
largest elastic modulus of any known material. CNTs can be made by chemical vapour 
deposition, carbon arc methods, or laser evaporation (Wang, 2005) and can be divided 
into single-walled carbon-nanotubes and multi-walled carbon-nanotubes (see figure 21). 
Single-walled carbon nanotubes (SWCNTs) provide good chemical stability, mechanical 
strength and a range of electrical conductivity. They are around ten times stronger and six 
times lighter than steel and they can behave as metals, semiconductors or insulators 
depending on their chirality and diameter (Lyons & Keeley, 2008). The chirality of the 
SWNT is related to the angle at which the graphene sheets are rolled up (Gooding, 2005). 
It has been also demonstrated (Gooding, 2005) that the conductivity properties of SWNTs 
can depend by the presence of catalytic particles, deriving from the fabrication process, 
the presence of defects in their chemical structure, ion-doping and side-wall 
functionalizations. 
 
  
Fig. 21. MWCNT and SWCNT (obtained with Nanotube Modeler © JCrystalSoft, 2010). 
Due to their high surface energies, SWCNTs are usually found in bundles or small 
aggregates composed of 10-100 tubes in parallel and in contact with each other. Multi-
walled carbon nanotubes (MWCNTs) are composed of several layers of concentric graphitic 
cylinders. They are regarded entirely as metallic conductors, making them more suitable for 
electrochemical applications (Lyons & Keeley, 2008). Anyway, thanks to their 
electrochemical properties, both multi and single-walled carbon nanotubes could be 
excellent candidates for the nanostructuration of electrodes used in amperometric biosensor 
devices. Pre-treatments of CNTs before their deposition onto electrode surfaces, cause the 
formation of open-ended tubes with oxygenated functional groups, crucial for the 
electrochemical properties of CNTs. Because of the hydrophobicity due to the CNT walls, in 
aqueous solution or in polar solvents the tubes have a tendency to rapidly coagulate. Thus, 
dispersing tubes is usually performed in non-polar organic solvents such as in 
dimethylformamide (DMF) or chloroform, or with the aid of surfactants or polymers, such 
as Nafion. The difficulty in dispersing nanotubes in aqueous solution though has been used 
SWCNT MWCNT 
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as an advantage in preparing nanotube modified electrodes where nanotubes dispersed in 
an organic solvent are dropped onto an electrode surface and the solvent allowed 
evaporating. It has been demonstrated that this kind of CNT deposition allows the 
nanotubes to be strongly adsorbed onto the electrode surface (Gooding, 2005). 
5.2.1.1 Electron transfer CNTs-protein 
The best strategy for successful enzyme biosensor fabrication is to devise a configuration by 
which electrons can directly transfer between the redox center of the enzyme and the 
underlying electrode. This is achievable because the physical adsorption or covalent 
immobilization of enzymes onto the surface of immobilized carbon nanotubes allows a 
direct electrical communication between the electrode and the active site of redox-active 
enzymes. It has been reported (Wang, 2005) that a redox enzyme, such as the glucose 
oxidase or cytochrome P450, adsorbs preferentially to edge-plane sites on nanotubes. Such 
sites contain a significant amount of oxygenated functionalities such as hydroxyl groups 
or carboxylic moieties formed during the purification of CNT, which provide sites for 
covalent linking of CNT to biorecognition elements (or other materials) or for their 
integration onto polymer surface structures (Wang, 2005). Other oxygenated moieties, 
useful for the protein immobilization, can be also formed by the breaking of carbon-
carbon bonds at the nanotube ends and at defect sites present on the side-walls. The 
nanotubes and enzyme molecules are of similar dimensions, which facilitate the 
adsorption of the enzyme without significant loss of its shape or catalytic function. It is 
thought that the nanotube directly reaches the prosthetic group such that the electron 
tunnelling distance is minimized. In this way, loss of biochemical activity and protein 
denaturation are prevented (Lyons & Keeley, 2008). 
5.2.1.2 Nanostructuring electrode surfaces with carbon nanotubes 
There have been a number of approaches to randomly distributing the CNTs on electrodes 
by dispersing the nanotubes with a binder such as dihexadecyl-hydrogen phosphate or 
Nafion, forming the nanotube equivalent of a carbon paste which can be screen printed, 
forming a nanotube-teflon composite, drop coating onto an electrode without any binders, 
preparing a nanotubes paper as the electrode and abrasion onto the basal planes of pyrolytic 
graphite. The resultant electrode has randomly distributed tubes with no control over the 
alignment of the nanotubes. To better control the alignment of nanotubes a more versatile 
approach to producing aligned carbon nanotube arrays is by self-assembly, by using self-
assembled monolayers (after the functionalization of the carboxylic-ends of CNTs with 
carbodiimide groups and thiols), or by directly growing of aligned nanotubes onto the 
surface. To do this plasma enhanced chemical vapor deposition using a nickel catalyst on a 
chromium coated silicon wafer can be used (Gooding, 2005). Advantages in using this 
method are the robustness of these electrodes and also the control over the density of the 
CNT film by controlling the distribution of the catalyst on the surface (Salimi et al., 2005). 
Figure 22 reports a comparison between SEM images of MWCNTs (on the bottom) and 
MWCNTs covered by 1 layer of CYP3A4 (on the top). The CNTs has been deposited by drop 
casting technique onto the electrode surface (30μL of a solution 1mg/ml of MWCNTs in 
chloroform). In the figure is visible the increase of apparent CNTs diameter due to the 
presence of a layer of CYP3A4 (on the top), that has been deposited by drop casting onto the 
CNT-surface. 
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Fig. 22. Comparison between SEM images of MWCNTs (on the bottom) and MWCNTs 
covered by 1 layer of CYP3A4 (on the top), both at 80,000X of magnification.  
5.2.1.3 Enhancement of catalytic current with CNTs 
The chemical modification of electrode surfaces with carbon nanotubes has enhanced the 
activity of electrode surfaces with respect to the catalysis of biologically active species such 
as hydrogen peroxide, dopamine and NADH. Furthermore, multi-walled carbon nanotubes 
have exhibited good electronic communication with redox proteins where not only the 
redox center is close to the protein surface such as in Cytochrome c (Zhao et al., 2005) and 
horseradish peroxidase, but also when it is deeply embedded within the glycoprotein such 
as is found with glucose oxidase (Gooding, 2005). A recent study (Carrara et al., 2008) 
demonstrated the enhancement of the catalytic current in a P450-based enzyme sensor in the 
case of electrodes modified with MWCNT, with respect to the case of both the bare 
electrodes and the electrode modified with gold nanoparticles. In figure 23, a comparison 
between cyclic voltammograms of screen-printed bare electrode (1), electrode modified with 
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Au nanoparticles and CYP11A1 (2) and with MWCNTs and CYP11A1 (3) is reported. In 
these voltammograms, a huge increase of the current peak is observable in the case of the 
P450 working electrode modified with gold nanoparticles respect to the bare electrode, but a 
further enhancement of the peak current is clearly visible in the case of MWCNTs-modified 
electrode with P450 (Carrara et al., 2008). 
 
 
Fig. 23. Cyclic voltammograms of screen-printed bare electrode (1), electrode modified with 
Au nanoparticles and CYP11A1 (2) and with MWCNTs and CYP11A1 (3), (Carrara et al., 
2008). Reprinted from Biosensors and Bioelectronics, Vol. 24, Sandro Carrara, Victoria V. 
Shumyantseva, Alexander I. Archakov, Bruno Samorì, “Screen-printed electrodes based on 
carbon nanotubes and cytochrome P450scc for highly sensitive cholesterol biosensors”, 
Pages No. 148–150, Copyright (2008), with permission from Elsevier. 
This is the direct proof that the CNT improve the electron transfer between the electrodes 
and the heme groups of the cytochromes. Moreover, in the presence of MWCNT, the peak is 
shifted in the positive direction of the voltage axis, because P450 is easier reduced in the 
presence of CNT, i.e. it is easier to reduce the heme iron incorporated in the protein core.  
6. Conclusions 
In this chapter the feasibility of cytochrome P450 as probe molecule for the design of an 
electrochemical biosensor for drug detection in biological fluids has been investigated. 
Cytochromes P450 have been chosen since they are known to be involved in the metabolism 
of over 1,000,000 different xenobiotic and endobiotic liphophilic substrates, in particular in 
the metabolism of ∼75% of all drugs. The majority of cytochromes involved in drug 
metabolism exhibits a certain genetic polymorphism, i.e. mutations in the CYP genes that 
can cause the enzyme activity to be abolished, reduced, altered or increased, with 
substantial consequences in drug metabolism, such as an exaggerated and undesirable 
pharmacological response. In order to individually optimize an ongoing drug therapy, it is 
required to measure the plasma concentrations of drugs or their metabolites after the 
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administration. This is needed for really understand how the patient metabolize drugs at the 
moment of the pharmacological cure. It is a strong need since most effective drug therapies 
for major diseases still provide benefit only to a fraction of patients, typically in the 20 to 
50% range. At the present state-of-the-art the technology allows only to check the genetic 
predisposition of patients to metabolize a certain drug, without taking into account the 
many factors that can influence drug metabolism, such as lifestyle, drug-drug interactions 
and cytochrome P450 daily variation of the polymorphism. Although CYPs are capable in 
general of catalyse around 60 different classes of reactions, they have a number of features 
in common, such as the overall fold structure, the presence in their active site of the heme 
group, that allow the electron transfer to catalyze substrate oxidations and reductions, and 
the typical catalytic cycle which requires oxygen and electrons as part of the process of 
metabolism. 
CYPs ability to metabolize a broad spectrum of endogenous substances, e.g., fatty acids, 
steroid hormones, prostaglandins and in particular foreign compounds such as drugs, has 
made this enzyme family interesting as recognition element for biosensing. P450-based 
biosensors are of great interest due to the possibility of developing applications such as the 
detection of analytes and drugs, since the currently-available methods used for in vitro 
quantifying the levels of drugs in biological fluids are time-consuming and expensive. A 
cytochrome P450 biosensor may be a promising alternative that would provide quick 
measurements for drugs and metabolites with a cheap, simple to use, rapid and, in some 
instances, disposable equipment, which also supplies good selectivity, accuracy and 
sensitivity. The most suitable approach for the design of a CYP-based biosensor is the direct 
mediatorless electron supply from an electrode to the redox active group of the CYP, thus 
leading a direct flow of electrons to the enzyme. In the development of this mediator-less 
approach, the immobilization of CYP onto the electrode surface has to be deeply controlled 
in order to obtain a high probability for the protein to be attached to the electrode in a 
proper orientation that could optimize the electron transfer to the heme group. In this 
chapter different techniques for the immobilization of CYPs onto the electrode surface have 
been described as reported in literature, focusing the attention also on the use of 
nanostructures (e.g. carbon nanotubes), to improve the biosensor sensitivity.  
Finally, a list of drugs which have been detected with several CYP isoforms has been 
reported with data found in literature as well as data obtained by the authors. It is possible 
to conclude that cytochromes P450 may be used to detect drug compounds also reaching the 
therapeutic ranges found in the patients’ blood, thanks to improved performances due to 
nanostructured-electrodes. Since for the treatments of some of the most common diseases 
(e.g. in anti-cancer therapies), more than one drug are administrated contemporaneously, an 
array-based biosensor able to measure multiple-drug concentrations at the same time, by 
using different CYP isoforms, would find several practical applications and it could be a 
first step toward the development of a real chip for personalized-medicine. Electrode 
miniaturization is the next mandatory step in order to test the real feasibility of this 
cytochrome-based biosensor as a fully-implantable device for the detection of drugs and 
metabolites, as much as the evaluation of the biocompatibility of all chip’s components, with 
particular regard to nanostructures and cytochrome citotoxicity. Finally, kinetics studies of 
drugs should be carried out in order to better understand drug-drug interaction phenomena 
and the reactions between drugs and cytochrome P450, with regard to enzyme heterotropic 
kinetics and its effects on drug metabolism. 
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A cytochrome P450-based biochip for drug detection should be a very powerful platform for 
personalization of drug therapy thanks to the key role of P450. However, as it has been 
shown in this chapter, different P450 isoforms may have the same drug compound as 
substrate and different drugs may be substrates of the same P450 protein. Proper strategies 
to develop the multiplexing P450-based biosensor arrays must be studied, considering 
problems due to multiple enzyme-substrate interactions and in the meanwhile maintaining 
high reliability and low cost of experimentation.  
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